Parkway Life REIT – No major refinancing risks until 2HFY11

Thursday, June 11, 2009

PREIT posted a 16.6% rise in 1Q09 DPU to 1.89 cts (annualized yield of 8.7%). Gross revenue jumped 37.6% yoy to $16.3m, with the additional rent from the Japan properties contributing to 83% of the growth. Revenue growth was also driven by an upward revision of rents at the Singapore hospitals by 6.25% for the 2nd year of the lease, which started from Aug 08.

The net property income (NPI) margin remained stable at 93% despite higher expenses incurred for the Japan properties. This is a result of its properties being leased on a triple net basis, in which the lessees bear all property operating expenses. Distributable income grew a milder 16.6% to $11.4m as a result of higher financing cost due to acquisitions of the Japan properties in 2Q08 and 3Q08 being debt-funded.

Major refinancing risks will not kick in until Sep/Oct-2011. PREIT’s entire debt portfolio of $247.5m has a weighted average tenor of 2.4 years. Its effective interest cost of 2.89% is one of the lowest in the sector and is fixed for the next three years. Its low gearing of 23.3% leaves a debt headroom of $305.m before the 40%-gearing level is reached.

There is still potential for asset enhancement initiatives at its under-optimized pharmaceutical product distribution and manufacturing facility in Japan, which would not burden its balance sheet while providing a little upside to earnings. Otherwise, we should expect flatter yoy growth from the next quarter on, given the diminished effect of inorganic growth.

We believe PREIT is on track to deliver our forecast DPU of 7.1 cts as 93% of its leases are structured with downside protection to rent revenues. Our earnings estimates remain intact while target price has been raised to $1.09 from $0.94 to reflect the easing equity risk premium over the past 6 weeks. Maintain BUY.

Sponsored Links

Related Posts by Categories



Comments

No response to “Parkway Life REIT – No major refinancing risks until 2HFY11”
Post a Comment | Post Comments (Atom)

Post a Comment

Disclaimers

These articles are neither an offer nor the solicitation of an offer to sell or purchase any investment. Its contents are based on information obtained from sources believed to be reliable and we make no representation and accepts no responsibility or liability as to its completeness or accuracy. We share them here as they are very informative, we claim no rights to these articles. If you own these articles, and do not wish to share it here, please do inform us by putting a comment and we will remove them immediately. We do not have any intentions to infringe any copyrights of yours. This is a place to keep record on the analyst recommendation for our own future references. We hope this serves as a record in the future, also make them searchable. We bear no responsibility for any profit, loss generated from these reports.
 
Citrus Pink Blogger Theme Design By LawnyDesignz Powered by Blogger